BR112022020243A2 - Formas cristalinas de (9r,13s)-13-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1,6-diidropirimidin-1-il}-3-(difluorometil)-9-metil-3,4,7,15-tetraazatriclo[12,3,1,02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-ona - Google Patents

Formas cristalinas de (9r,13s)-13-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1,6-diidropirimidin-1-il}-3-(difluorometil)-9-metil-3,4,7,15-tetraazatriclo[12,3,1,02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-ona

Info

Publication number
BR112022020243A2
BR112022020243A2 BR112022020243A BR112022020243A BR112022020243A2 BR 112022020243 A2 BR112022020243 A2 BR 112022020243A2 BR 112022020243 A BR112022020243 A BR 112022020243A BR 112022020243 A BR112022020243 A BR 112022020243A BR 112022020243 A2 BR112022020243 A2 BR 112022020243A2
Authority
BR
Brazil
Prior art keywords
chloro
crystalline forms
pentaen
dihydropyrimidin
octadeca
Prior art date
Application number
BR112022020243A
Other languages
English (en)
Portuguese (pt)
Inventor
K Dilger Andrew
A Galella Michael
Smith Daniel
M Ziemba Theresa
Lüdeker David
Xiouras Christos
Ahuja Dipali
Angelina J Cleeren Dirk
Original Assignee
Bristol Myers Squibb Co
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Janssen Pharmaceutica Nv filed Critical Bristol Myers Squibb Co
Publication of BR112022020243A2 publication Critical patent/BR112022020243A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR112022020243A 2020-04-10 2021-04-09 Formas cristalinas de (9r,13s)-13-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1,6-diidropirimidin-1-il}-3-(difluorometil)-9-metil-3,4,7,15-tetraazatriclo[12,3,1,02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-ona BR112022020243A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063008161P 2020-04-10 2020-04-10
PCT/US2021/026663 WO2021207659A1 (en) 2020-04-10 2021-04-09 Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1 -yl)phenyl] -6-oxo- 1,6-dihydropyrimidin- 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.02·6] octadeca- 1(18), 2(6), 4, 14, 16-pentaen-8-one

Publications (1)

Publication Number Publication Date
BR112022020243A2 true BR112022020243A2 (pt) 2022-11-22

Family

ID=75690727

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020243A BR112022020243A2 (pt) 2020-04-10 2021-04-09 Formas cristalinas de (9r,13s)-13-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1,6-diidropirimidin-1-il}-3-(difluorometil)-9-metil-3,4,7,15-tetraazatriclo[12,3,1,02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-ona

Country Status (14)

Country Link
US (1) US20230151010A1 (https=)
EP (1) EP4132930A1 (https=)
JP (2) JP2023521411A (https=)
KR (1) KR20230008742A (https=)
CN (1) CN115916780A (https=)
AU (1) AU2021253946A1 (https=)
BR (1) BR112022020243A2 (https=)
CA (1) CA3179957A1 (https=)
CL (1) CL2022002786A1 (https=)
CO (1) CO2022016067A2 (https=)
IL (1) IL297206A (https=)
MX (1) MX2022012523A (https=)
PE (1) PE20231071A1 (https=)
WO (1) WO2021207659A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA71692A (fr) 2022-08-01 2025-05-30 Bristol-Myers Squibb Company Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique
KR20250136432A (ko) 2023-02-06 2025-09-16 브리스톨-마이어스 스큅 컴퍼니 밀벡시안 제약 조성물
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201908467RA (en) * 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2721243T3 (https=) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors

Also Published As

Publication number Publication date
EP4132930A1 (en) 2023-02-15
JP2026048873A (ja) 2026-03-17
PE20231071A1 (es) 2023-07-17
IL297206A (en) 2022-12-01
AU2021253946A1 (en) 2022-12-15
WO2021207659A1 (en) 2021-10-14
CO2022016067A2 (es) 2023-01-26
CL2022002786A1 (es) 2023-04-14
CN115916780A (zh) 2023-04-04
MX2022012523A (es) 2022-11-07
JP2023521411A (ja) 2023-05-24
US20230151010A1 (en) 2023-05-18
CA3179957A1 (en) 2021-10-14
KR20230008742A (ko) 2023-01-16

Similar Documents

Publication Publication Date Title
BR112022020243A2 (pt) Formas cristalinas de (9r,13s)-13-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1,6-diidropirimidin-1-il}-3-(difluorometil)-9-metil-3,4,7,15-tetraazatriclo[12,3,1,02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-ona
NZ627464A (en) Fungicidal pyrazole mixtures
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
NZ601121A (en) 5-alkynyl-pyrimidines
MX2019005009A (es) 1,2,4-triazolonas 2,4,5-trisustituidas.
NZ736665A (en) Heterocyclic amides as kinase inhibitors
MX2015018048A (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
CA2897273C (en) Benzylamine derivatives
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201391334A1 (ru) Ингибиторы hsp90
AR087794A1 (es) Proceso para preparar {1-{1-[3-fluoro-2-(trifluorometil)isonicotinoil]-piperidin-4-il}-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo, intermediarios de dicha sintesis y proceso para prepararlos
TN2014000033A1 (fr) Indazoles
PH12016500818A1 (en) Process for synthesis of an indoleamine 2,3-dioxygenase inhibitor
CO6680645A2 (es) Inhibidores de oxadiazol de la producción de leucotrieno
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
HK1215579A1 (zh) 被取代的2，3-二氫苯並呋喃基化合物和其用途
BRPI0412999A (pt) 2-aminotetralina substituìda para tratamento de depressão
MX374628B (es) Formulacion que comprende un agente hipolipidemico.
UA107562C2 (uk) Спосіб лікування псоріазу
CL2011002045A1 (es) Compuesto derivado de n-[(3e)-5-(cicloalquilamino)-5-oxo-1-fenilpent-3-en-2-il]benzamida, utiles en el tratamiento del prurito de causa desconocido o asociado a una enfermedad dermatologica tal como dermatitis atopica, psoriasis, urticaria, entre otras; combinacion farmaceutica.
ZA202400821B (en) Inhibitors of transglutaminases
NZ592392A (en) PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
JOP20230275A1 (ar) معدلات trex1
ZA202400823B (en) Inhibitors of transglutaminases
AR081514A1 (es) El compuesto 4-[etil(dimetil)amonio]butanoato, el metodo para la preparacion del mismo y el uso en el tratamiento de la enfermedad cardiovascular

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]